Aurinia Pharmaceuticals (AUPH)
Markets LUPKYNIS for lupus nephritis and develops additional autoimmune therapies.
Something off on this page? Send us feedback.
Markets LUPKYNIS, an oral treatment for active lupus nephritis, directly in the United States and supplies Otsuka for Europe and Japan. Revenue remains concentrated in this sole approved product, while aritinercept and Kezar-acquired zetomipzomib extend the clinical pipeline across autoimmune disease.
Markets LUPKYNIS (voclosporin), an oral calcineurin inhibitor for adults with active lupus nephritis, through a focused U.S. commercial organization. Most revenue comes from U.S. product sales; Otsuka commercializes the medicine in Europe and Japan under licensing and supply arrangements.
Develops aritinercept, a dual BAFF/APRIL inhibitor for autoimmune disease, and added zetomipzomib, an immunoproteasome inhibitor for autoimmune indications, through the acquisition of Kezar Life Sciences. The portfolio combines a marketed therapy with clinical-stage programs.
Depends substantially on LUPKYNIS, specialized third-party manufacturing, intellectual-property protection, and regulatory approval for pipeline candidates; generic applicants are challenging key U.S. patents.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Reiterate | Sector Perform | $15 | $16 | |
| Dec 3, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform | $16 | |
| Nov 7, 2025 | Jefferies | Upgrade | Hold | Buy | ||
| Nov 5, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform | ||
| Nov 5, 2025 | RBC Capital Mkts | Downgrade | Outperform | Sector Perform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $443.1M · Total debt $60.4M · Total assets $792.3M · Shareholders' equity $614.9M
- Revenue
- $83.2M
- Operating income
- $46.3M
- Net income
- $37.4M
No dividends on record.
| Institutions292 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 58.88% | 78.34M shares | |
| Insiders12 holders · as of Aug 25, 2026 | 3.18% | 4.23M shares | |
| Strategic holders1 holder · as of Feb 13, 2020 | 2.21% | 2.94M shares | |
| Otherremainder | ≈ 35.73% | 47.54M shares |
133.05M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Tang Capital Management LLCInstitution | 9.80% | 13.04M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.16% | 8.19M | 13Fas of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 4.22% | 5.62M | 13Fas of Jun 30, 2026 |
Nea Management Company, LLCInstitution | 2.98% | 3.97M | 13Fas of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 2.61% | 3.47M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Stephen P. Robertson | officer: Chief Legal Officer | −20,975 | $16.97 |
| May 29, 2026 | Kevin Tang | director, 10 percent owner, officer: Chief Executive Officer | +264,981 | $15.31 |
| Jun 1, 2026 | Kevin Tang | director, 10 percent owner, officer: Chief Executive Officer | +343,620 | $15.28 |
| Jun 2, 2026 | Kevin Tang | director, 10 percent owner, officer: Chief Executive Officer | +206,005 | $15.28 |
| Feb 27, 2026 | Kevin Tang | director | +516,439 | $13.99 |
- GSK (ADR)
Dominates lupus biologic market with Benlysta, FDA-approved for LN in 2020.
- AstraZeneca (ADR)
Saphnelo for SLE; anifrolumab IRIS Phase 3 in LN due 2027.
- Vera Therapeutics
Dual BAFF/APRIL inhibitor atacicept under FDA priority review for IgAN.
- Travere Therapeutics
Rare-kidney specialist with FILSPARI approved for IgAN and FSGS.
- Bristol-Myers Squibb
Broad immunology pipeline with SLE assets but no approved LN therapy.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals | $16.29 | −0.06% | $2.09B | 7.1 | 21.7 | 6.7 | +18.9% |
| GSK (ADR) | $50.93 | +1.00% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| AstraZeneca (ADR) | $164.32 | +1.65% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Vera Therapeutics | $35.20 | −1.35% | $2.56B | — | — | — | — |
| Travere Therapeutics | $67.85 | +0.95% | $6.25B | — | 34.3 | 10.6 | +48.2% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 15.8 | 12.9 | 3.5 | +6.1% |